for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aravive Inc

ARAV.O

Latest Trade

5.93USD

Change

0.10(+1.72%)

Volume

42,826

Today's Range

5.75

 - 

6.10

52 Week Range

3.34

 - 

15.62

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Aravive Says Co Added To Russell 2000 And Russell 3000 Indexes

* ARAVIVE ADDED TO THE RUSSELL 2000® AND RUSSELL 3000® INDEXES Source text for Eikon: Further company coverage:

BRIEF-Aravive Files For Offer And Resale Of Up To 931,098 Shares By Selling Stockholder - SEC Filing

* ARAVIVE INC FILES FOR OFFER AND RESALE OF UP TO 931,098 SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text for Eikon: https://bit.ly/2Vqye36 Further company coverage:

BRIEF-Aravive Says Rekha Hemrajani Has Resigned As CEO And As A Director

* ARAVIVE INC - REKHA HEMRAJANI HAS RESIGNED AS COMPANY'S CHIEF EXECUTIVE OFFICER AND AS A DIRECTOR

BRIEF-Aravive - Avb-500 Improves Anti-Tumor Effects When Combined With Anti-Angiogenic Bevacizumab Or Parp Inhibitor Olaparib For Uterine Cancer

* ARAVIVE ANNOUNCES AVB-500 IMPROVES ANTI-TUMOR EFFECTS WHEN COMBINED WITH ANTI-ANGIOGENIC BEVACIZUMAB OR PARP INHIBITOR OLAPARIB IN PRECLINICAL MODELS OF UTERINE CANCER Source text for Eikon: Further company coverage:

BRIEF-Aravive Announces Initiation Of Investigator-Sponsored Phase 1/2 Study Of AVB-500 In Combination With Avelumab

* ARAVIVE ANNOUNCES INITIATION OF INVESTIGATOR-SPONSORED PHASE 1/2 STUDY OF AVB-500 IN COMBINATION WITH AVELUMAB IN PATIENTS WITH ADVANCED UROTHELIAL CARCINOMA (COAXIN)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up